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The acylation of bioactive primaquine-based imidazolidin-4-ones was studied using Na-Boc-protected
glycine as acylating agent. Two synthesis routes, eight different coupling methods and seven distinct
solvents were compared. Mild carbodiimide-based couplings on high dielectric constant solvents such as
DMF or MeCN increased acylation yields, whereas alcohols inhibited carbodiimide-mediated acylations
to take place. Achievement of the synthetic goals was limited by the size of the imidazolidin-4-one ring
substituents R1, R2 and R3, but resort to MW-assisted synthesis allowed overcoming such obstacle,
though with very modest reaction yields. All reactions involving a Boc-protected amino acid were re-
gioselective, independent of reaction conditions employed. In contrast, regioselective acetylation of the
imidazolidin-4-ones could only be achieved by resort to very mild coupling procedures.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Primaquine (PQ, 1) is an antimalarial well known for its excel-
lent gametocytocidal activity but also for its toxicity. The main
factor for this toxicity is the nature of its major metabolites. Some of
the undesired PQ metabolic pathways can be overridden by mod-
iﬁcation of the drug’s structure, e.g., protection of its terminal pri-
mary amino group.1–5
With this purpose in mind, our research group has been de-
veloping imidazolidin-4-one derivatives (2) of PQ a-aminoamidesOH, Na-Boc-protected amino
loromethane; DIEA, N-ethyl-
lcarbodiimide; DIU, N,N0-dii-
-dimethylformamide; DMSO,
ass spectrometry; Gly, glycine
tetramethylaminium hexa-
ole-1-yl)-1,1,3,3-tetramethyl-
zotriazole; MW, microwave
, 2-(1H-benzotriazole-1-yl)-
triethylamine; THF, tetrahy-
ied as Supplementary data in
: þ351 220402659.
All rights reserved.(3).6–9 The latter are prepared in a previous step where the N-ter-
minal amine of PQ is acylated with Na-Boc-protected amino acids
(BocAAOH), thus further insertion of the imidazolidin-4-one moi-
ety also avoids compound degradation by the action of amino- and
endopeptidases.10,11 Imidazolidin-4-ones 2 have shown antimalar-
ial activity against Plasmodium berghei comparable or higher than
that of the parent PQ,7 which prompted us to engage in further
modiﬁcation of these compounds through acylation of the imida-
zolidin-4-one N-1 with another amino acid, yielding compounds 5.
Given that structures 2 bear two secondary amines able to be ac-
ylated, i.e., at quinoline’s C-8 and imidazolidin-4-one’s N-1, regio-
selectivity was a relevant issue to the pursuit of our synthetic goals.
Previous reports described Na-protected amino acids as selective
sulfanilamide acylants, where only monoacylation at the sulfani-
lamide’s N-4 occurred by employing classical carbodiimide-medi-
ated couplingmethods, leaving the sulfonamide’sN1 unreacted.12,13
Thus, it was reasonable to assume that by equally resorting to
a BocAAOH as acylating agent and to carbodiimide-mediated cou-
pling, wewould achieve our purpose, i.e., regioselective production
of compounds 5. The regioselectivity and efﬁciency of the coupling
reactions were tested using imidazolidin-4-ones 2a and 2b (2 in
Scheme 1 with, respectively, R1¼H, R2¼R3¼Me and R1¼H, R2 and
R3¼–(CH2)5–) as starting materials. Different coupling methods,
reaction conditions and solvents were assayed, so we now wish to
herein report and discuss the results thus obtained.
Table 1
Acylation of 2a with BocGlyOH to yield 6a: comparison of coupling methods
Reaction Condensation agents Solventc Yield/%
A None (reﬂux) DMF (36.7) 0d
B DIPCDI 10
C DIPCDI/HOBt 87
D DIPCDI/DMAP 4
E TBTU/DIEAa 21
F HBTU/DIEAa 59
G HCTU/DIEAa 10
H BocGlyOSub 15
C2 DIPCDI/HOBt MeCN (37.5) 76
C3 MeOH (32.6) 0e
C4 DCM (9.1) 34
C5 THF (7.6) 0d
C6 DME (7.2) 48
C7 MeOH/DMF 1:1 (v/v) 0e
a In a 1:1 proportion, i.e., only 5 equiv of DIEAwas added, as 3 equiv TEAwas used
in the ‘base conditions’ of all reactions assayed.
b Use of the active ester of BocGlyOSu (5 equiv) instead of BocGlyOHþcoupling
agent.
c Solvent dielectric constants at 20 C, as taken from http://organicdivision.org/
organic_solvents.html, are given in parenthesis.
d Quantitative recovery of unreacted 2a.
e Quantitative recovery of 2aþquantitative formation of diisopropylurea (DIU).
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Scheme 1. Synthetic routes to PQ-derived imidazolidin-4-ones 2 and their N1-ami-
noacyl derivatives 5: (i) 1 equiv BocAAOH, 1.1 equiv DIPCDI, 1.1 equiv HOBt, 1 equiv
TEA, DCM, 0 C/rt; (ii) neat TFA, rt, 30% aq Na2CO3, extraction with CHCl3; (iii)
R2(C]O)R3, TEA, reﬂuxing MeOH;6 (iv) 5 equiv BocAAOH, 5 equiv condensation
agent(s), 3 equiv TEA, solvent, 10 C/rt, inert atmosphere; (v) 5 equiv BocAAOH,
5 equiv DIPCDI, 5 equiv HOBt, 3 equiv TEA, DMF, MW irradiation (150 W, 20 min,
90 C); (vi) 2 equiv TEA, 15 equiv propanone or 5 equiv cyclohexanone, MeOH, mi-
crowave irradiation (150 W, 10–20 min, 90–120 C); (vii) TFA/DCM 30%, rt, Na2CO3 aq
30%, extraction with CHCl3 or DCM.
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2.1. Synthesis route and coupling method
Synthetic route A on Scheme 1 was initially taken to reach the
target N1-acyl-imidazolidin-4-ones 6. To this purpose, compound
3a was condensed with BocGlyOH to yield the corresponding Na-
Boc-protected dipeptidylprimaquine 4a. This was then reactedwith
propanone by a previously described method6 to insert the imi-
dazolidin-4-one ring between both amides, but 4a was quantita-
tively recovered unreacted. This route was assayed using other
compounds 3, BocAAOH and ketones, but formation of structures 6
was never detected (data not shown).
Failure of preparing structures 6 through route A was attributed
to steric constraints, as conversion of 4 into 6would require cis/trans
isomerisation of amide bonds followed by condensation of the ke-
tone and concomitant ring closure at the middle of the peptide
backbone, i.e., surroundedbyaminoacid sidechainsR1andR4aswell
as by the Boc protecting group. In an attempt to obviate the putative
steric constraints behind the failure of route A, microwave-assisted
synthesis was carried out. To that purpose, a commercially available
monomode microwave (MW) instrument equipped with a sealed
reactor, the CEMDiscover BenchMate, was used. This reactor has
the advantage to focus the microwave irradiation on the vessel in
order to avoid dispersion and the ability to maintain the target
temperature while subjecting the reaction mixture to continuous
irradiation with microwaves by cooling the reaction vessel with
a stream of nitrogen. However, not even when resorting to MW-
assisted synthesis at temperatures as high as 120 C andMWpower
of 150Wwas synthetic route A by any means productive.In view of the above, we stepped forward to assay route B
(Scheme 1) in order to reach our synthetic goal. Thus, 3awas ﬁrstly
reacted with propanone to yield 2a, as previously reported.6 Con-
densation of 2a with BocGlyOH was then carried out by seven
different coupling methods, starting from 1 mol equiv (1 equiv) of
2a and 5 equiv of BocGlyOH as reactants and using N,N-dime-
thylformamide (DMF) as solvent (Table 1, entries A–G). As expected,
the reaction did not take place by simply reacting the amine and
acyl components under reﬂux, in the absence of a condensation
agent (entry A). In the remaining cases, the reaction always led to
formation of a single product, monoacylated at the imidazolidin-4-
one’s N-1 (6a), as conﬁrmed by nuclear magnetic resonance (NMR).
The same result was observed when replacing the Boc-
GlyOHþcoupling agents mixture by the BocGlyOH succinimide
active ester, BocGlyOSu (entry H). The diisopropylcarbodiimide/1-
hydroxybenzotriazole (DIPCDI/HOBt) method14 was the most efﬁ-
cient (entry C), whereas the worst result was obtained by re-
placement of HOBt with 4-(N,N-dimethyl)aminopyridine (DMAP)15
as auxiliary nucleophile (entry D). Oddly, more recent and potent
HOBt-derived amminium salts such as TBTU16 (entry E) or HCTU17
(entry G) were amongst the least effective to promote the desired
condensation, even when reactions were carried out at room
temperature from the start, i.e., without an initial w3 h phase at
10 C (data not shown). Remarkably, HBTU-mediated condensa-
tion (entry F) led to a substantially higher yield, despite HBTU
differs from TBTU only at its counter-ion (hexaﬂuorophosphate
instead of tetraﬂuoroborate, respectively).
Acidolytic removal of Boc18 from 6a to yield 5a was always
successfully achieved by using 30% triﬂuoroacetic acid (TFA) in
dichloromethane (DCM), as conﬁrmed by NMR and electrospray-
ionisation mass spectrometry (ESI-MS) analyses.
The synthetic route based on DIPCDI/HOBt condensation in DMF
(entry C) followed by Boc removal with 30% TFA in DCM has been
successfully applied to prepare a set of compounds 5 that differed
only at the amino acid attached to N1 (different R4).19
2.2. Solvent
The best condensation method, according to the previous sec-
tion, was further assayed in six additional solvents, namely, DCM,
tetrahydrofuran (THF), methanol (MeOH), acetonitrile (MeCN), 1,2-
dimethoxyethane (DME) and MeOH/DMF 1:1 (v/v), to test for
coupling efﬁciency. The solvent collection originally chosen
N. Vale et al. / Tetrahedron 64 (2008) 11144–1114911146included a larger set of both protic and aprotic solvents having
a wide range of dielectric constants, but not all of them could be
used either due to solubility problems or melting points in-
compatible with the fact that carbodiimide activation usually re-
quires use of low temperatures (10 C).20
In all those solvents where the condensation reaction actually
took place (see below), regioselective formation of 6a was consis-
tently observed, though to different extents (Table 1, entries C and
C2–C7). Acylations are usually performed in dry inert solvents in the
presence of a non-nucleophilic tertiary amine (TEA, DIEA, N-meth-
ylmorpholine, etc.),21 with DCM being one of the most popular sol-
vents for peptide couplings.22 However, in our particular case, the
synthesis carriedout inDCMhadonlyamodestyield (34%), as shown
in Table 1 (entry C4), quite below the yields recorded for the same
reaction in DMF (87%, entry C) or MeCN (76%, entry C2). In contrast,
reactions in THF, MeOH or DMF/MeOH1:1 (v/v) did not take place at
all, as the starting compound (2a) was quantitatively recovered to-
gether with the DIPCDI-derived urea, diisopropylurea (DIU).
As inferred from data in Table 1, the synthesis yield cannot be
ﬁrmly correlated with the solvent’s dielectric constant. Even so, the
latter seems to have a key role, as higher yields were obtained in
solvents with higher dielectric constants, with the exception of
reactions carried out in MeOH-containing media. The explanation
for this exception most probably lies on the fact that MeOH reacts
with DIPCDI to form the corresponding O-methyl-isourea (Scheme 2).
Reaction of alcohols with carbodiimides has been explored by
Aresta and co-workers,23 who investigated the factors that in-
ﬂuence the yield and selectivity of reaction of N,N0-dicyclohexyl-
carbodiimide (DCCI) with alcohols and concluded that the
alkylation is dependent on the nature and rate of addition of the
alcohol to the C]N bond, and that reaction rate generally increases
with temperature and the presence of a catalyst. The occurrence of
such a reaction in our case simultaneously explains the extensive
formation of DIU and the fact that synthesis of 6a is completely
inhibited in a solvent mixture that contains 50% MeOH.
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Scheme 2. Reaction of MeOH with DIPCDI to yield dimethyl ether and DIU.2.3. Substituent groups at the imidazolidin-4-one’s C-2
and C-5 positions
Condensation of 2b with BocGlyOH was never achieved re-
gardless of the solvent or condensationmethod employed. This was
attributed to steric constraints imposed by the cyclohexane ring on
the imidazolidin-4-one’s C-2 spiro-carbon neighbouring the N-1
nitrogen that should be acylated. This observation was consistent
with other failed attempts to obtain structures 6 from precursors 2
bearing large R1, R2 and R3 groups,19 showing the relevance of steric
constraints on positions adjacent to the imidazolidin-4-one’s N-1
atom. Similar difﬁculties were reported for the solid-phase
synthesis of Leu-Enkephalin peptidomimetics based on the imi-
dazolidin-4-one scaffold, where resin-bound dipeptide imidazoli-
din-4-ones containing two methyl groups at C-2 failed to give the
desired N1-acyl derivatives.24MW-assisted synthesis was tried on the acylation of 2b with
BocGlyOH and found to lead to formation of 6b through a 20-min
reaction under MW irradiation at 150W and 90 C (all other re-
action parameters were kept unchanged respective to the best
synthesis of 6a). Nonetheless, 6b was obtained in a very modest
yield (w13%).
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Other N-acylations of imidazolidin-4-ones 2 with Boc-amino
acids were carried out both with and without MW irradiation, in all
cases for 20 min at 90 C so that MW power would be the only
variable (data not shown). This allowed to observe that (i) all suc-
cessful acylations were regioselective at the imidazolidin-4-one’s
N-1 even at 90 C; (ii) acylations that occurred in the absence of
MW were equally efﬁcient (i.e., similar yields) by MW-assisted
synthesis as long as the same temperature was used; (iii) MW ir-
radiation enabled some sterically demanding N1-acylations to take
place, though in modest yields.
In view of the above, it appears that MW-assisted N1-acylation
of imidazolidin-4-ones 2 is not necessary except for speciﬁc cases
where steric constraints disable the reaction to take place by non-
MWapproaches. Though reactions were substantially faster at high
temperatures (promoted or not by MW-irradiation), these should
be avoided when using chiral amino acids to prevent them to un-
dergo base (TEA)-catalysed racemisation.
2.4. Regioselectivity
Reaction regioselectivity was a relevant issue, as the two sec-
ondary amino groups in 2a could attack the acylating agent to form
tertiary amides. It is true that electron delocalisation of the nitrogen
lone pair of the 8-aminoquinoline moiety to the quinoline ring (2,
Scheme 1) can account for a lower nucleophilicity of the 8-amino
group as compared to the imidazolidin-4-one N-1 amine. However,
the complete absence of N-acylation at the 8-amino group was
noteworthy and made us wonder if Boc-amino acids were acting as
selective acylants, as previously observed in similar N4-acylations
of sulfanilamides.12,13
To further investigate whether the quinoline’s 8-amino sub-
stituent was completely inert towards acylation, we worked on the
acetylation of 2a by two different methods. Acetyl was chosen as
acyl component to differ from the amino acid acylants and to rule
out, or not, the putative inﬂuence of the latter on regioselectivity.
Thus, 2a was reacted in DMF with acetic anhydride, instead of
BocGlyOH, as above described. Again, only the N1-monoacylated
product 7 was formed in this case (ca. 83% yield), as conﬁrmed by
ESI-MS and NMR. However, when 2a was dissolved in neat acetic
anhydride (20 equiv) under reﬂux, as described for the synthesis of
5-chloroarylidene derivatives of imidazoline-4-ones,25 only the
N,N0-diacetyl derivative 8 was produced (94% yield).
N
N
Me
OMe
N
N
O
Me
Me
Me
O
7, X=H
8, X=COMe
X
N. Vale et al. / Tetrahedron 64 (2008) 11144–11149 11147Altogether, these ﬁndings show that imidazolidin-4-ones like 2a
are regioselectively acylated at N-1 by Boc-amino acids even under
stronger conditions (high temperature, 150 W MW irradiation),
whereas the use of a general acylant as acetic anhydride would
require very mild coupling conditions in order to keep such
regioselectivity.
It could be argued that formation of 8 by reﬂuxing 2a in acetic
anhydride might be due to the large excess of the acylating agent
used; however, if this was entirely true, reactions with BocGlyOH,
carried out with a ﬁvefold molar excess of the acylating species,
should have given at least a small amount of the diacyl derivative.
It could also be claimed that the nature of the acylating species
is different in reactions with acetic anhydride, as this is by itself, as
a symmetrical anhydride, the active acylating species; nevertheless,
the majority of condensation methods assayed with BocGlyOH had
DIPCDI as coupling agent, thus leading to an O-acyl-isourea in-
termediate 9 that is readily attacked by either an auxiliary nucle-
ophile such as HOBt, the amine component to be acylated, or
anothermolecule of BocGlyOH, inwhich case an active symmetrical
anhydride will also be formed (Scheme 3). So, BocGlyOH activation
via a symmetrical anhydride surely also happened in most re-
actions tested and such did not affect reaction regioselectivity.
Moreover, just to ensure that it was not the ‘anhydride nature’ that
dictated the non-regioselective formation of the diacyl derivative 8,
we have used acetic anhydride, instead of acetic acid, in the re-
action that was carried out under exactly the same conditions as
those usedwith BocGlyOH (DIPCDI/HOBt in DMF, entry C in Table 1).
As above referred, such reaction led to regioselective acylation of
the N-1 nitrogen in 2a, yielding compound 7.R OH
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Scheme 3. Parallel pathways in carbodiimide/HOBt-mediated acylation of a secondary
amine.So, overall, it seems that the regioselectivity consistently ob-
served in the acylations of imidazolidin-4-ones 2 with Boc-amino
acids depends on the relative nucleophilicity of the two secondary
amine nitrogens and, mainly, on the nature of the acylating agent.This is consistent with our previous ﬁndings that regioselective
acylation of sulfanilamides with Na-protected amino acids is highly
dependent on the acidity of the sulfonamido’s nitrogen (N-1).12,13 In
the present case, the preferential acylation of the imidazolidin-4-
one’s N-1 nitrogen atom may be ascribed to its higher basicity
(pKaw5)
8,26 when compared to that of the quinoline’s nitrogen
atom (pKaw3).
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3. Concluding remarks
N1-Acyl-imidazolidin-4-ones 5 can be successfully prepared
through regioselective N1-acylation of the imidazolidin-4-one
precursors 2 bymeans of mild peptide condensationmethods. High
dielectric constant solvents such as DMF or MeCN increase acyla-
tion yields, whereas alcohols should be avoided when activation of
the acyl component is promoted by carbodiimides. Gathering the
present with previous19 ﬁndings led to conclude that the success of
the coupling reactions was limited by the size of the imidazolidin-
4-one ring substituents R1, R2 and R3, but resort to MW-assisted
synthesis is a way to overcome such obstacle, enabling the suc-
cessful acylation of bulkier imidazolidin-4-ones, though with
modest yields.
Boc-amino acids seem to act as selective acylating agents for
imidazolidin-4-ones 2, in a way parallel to that previously found on
similar reactions involving N4-acylation of sulfanilamides. Ongoing
computational studies to establish the molecular basis for the
regioselectivity herein described will be timely reported.
4. Experimental section
4.1. Chemicals and instrumentation
Na-tert-Butyloxycarbonylglycine (BocGlyOH), HBTU and HCTU
were purchased to NovaBiochem (VWR International, Portugal).
TBTU was from Bachem (Switzerland). All solvents (p.a. quality)
were from Merck (VWR International, Portugal) and dried over
activated 4 Å molecular sieves prior to usage. All remaining
chemicals were from Sigma–Aldrich (Portugal). Silica gel for col-
umn chromatography (ref. 60A, 35–70 mm; 550 m2/g) was from SDS
(France).
Microwave reactions were carried out in Discover Bench-
MateTM (CEM) microwave instruments equipped with 10 mL ves-
sels. NMR spectra were recorded on a Bruker AMX 300
spectrometer and ESI-MS spectra were acquired on a Finnigan
Surveyor LCQ DECA XP Max spectrometer.
4.2. Synthesis
Synthesis and spectroscopic data are only given in detail for
those compounds relevant for the present study. A larger set of N1-
acyl-imidazolidin-4-ones 5 have been prepared as described for 5a
to be evaluated as potential antimalarials, as reported elsewhere.19
NMR data are abbreviated as follows: br s, broad singlet; d, doublet;
dd, double doublet; dq, double quartet; dt, double triplet; d,
chemical shift (in ppm); m, unresolved multiplet; q, quartet; Q,
hydrogen on quinoline ring; QC, carbon on quinoline ring; s, sin-
glet; t, triplet.
4.2.1. Acylation of 2a with Boc-glycinedsynthesis of 6a (entries
B–C7, Table 1)
Compound 2a (1 mmol) was suspended in solvent (20 mL), TEA
(3 equiv) and the mixture was stirred in an ice-water/acetone/NaCl
bath (10 C) for 20 min, under inert atmosphere. After addition of
either BocGlyOSu (5 equiv) or BocGlyOH (5 equiv) plus the coupling
agent(s) (5 equiv), the mixture was kept at 10 C for further 4 h,
under stirring. The temperature was then slowly increased to
N. Vale et al. / Tetrahedron 64 (2008) 11144–1114911148þ10 C and thus maintained till the end of reaction (24 h). The solid
phase formed in DIPCDI-mediated reactions was removed by suc-
tion ﬁltration and identiﬁed as DIU. The liquid phase was evapo-
rated at 90 C in vacuo to dryness and the resulting residue was
dissolved in 40 mL of DCM. This solution was washed three times
with 15 mL portions of 10% aq NaHCO3 and the organic layer dried
over anhydrous MgSO4 and evaporated to dryness. The residue was
submitted to column chromatography on silica using DCM/acetone
as eluent. The chromatographically homogeneous product was
isolated as yellow-orange oil and identiﬁed as 6a.
4.2.1.1. 1-[(3-tert-Butyloxycarbonyl)-3-aza-1-oxopropyl]-3-{4-[(6-
methoxyquinolin-8-yl)-amino]pentyl}-2,2-dimethylimidazolidin-4-
one (6a). dH (CDCl3, 300 MHz) 8.51 (dd, J¼4.20, 1.38 Hz, 1H, Q2),
7.92 (dd, J¼8.26, 1.42 Hz, 1H, Q4), 7.30 (dd, J¼8.28, 4.20 Hz, 1H, Q3),
6.34 (d, J¼2.45 Hz, 1H, Q5), 6.28 (d, J¼2.43 Hz, 1H, Q7), 6.01 (d,
J¼8.22 Hz, 1H, –NH–CH(CH3)–CH2–), 5.35 (br s, 1H, –NH–CO–O–),
3.95 (s, 2H, –CO–CH2–N–), 3.89 (s, 3H, CH3–O–), 3.81 (d, J¼4.31 Hz,
2H, –CO–CH2–NH–), 3.69–3.63 (m, 1H, –NH–CH(CH3)–CH2–), 3.30–
3.18 (m, 2H, –(CH2)2–CH2–N–), 1.84–1.72 (m, 4H, –CH2–CH2–CH2–),
1.60(4) and 1.59(9) (sþs, 6H, –N–C(CH3)2–N–), 1.44 (s, 9H, –O–
C(CH3)3), 1.31 (d, J¼6.30 Hz, 3H, –NH–CH(CH3)–). dC (CDCl3,
75.4 MHz) 166.03 (–CO–CH2–N–), 165.36 (–CO–CH2–NH–), 159.50
(QC6), 155.84 (–CO–O–), 145.03 (QC2), 144.43 (QC8), 135.42 (QC4),
134.89 (QC10), 129.99 (QC9), 121.99 (QC3), 96.90 (QC7), 91.88 (QC5),
80.91 (–O–C(CH3)3), 79.99 (–N–C(CH3)2–N–), 55.33 (CH3–O–), 47.92
(–NH–CH(CH3)–CH2–), 47.16 (–CO–CH2–N–), 43.80 (–CH2–NH–CO–
), 39.91 (–(CH2)2–CH2–), 34.13 (–CH2–(CH2)2–), 28.42 (–O–C(CH3)3),
25.84 (–N–C(CH3)(CH3)–N–), 24.60 (–N–C(CH3)(CH3)–N–), 24.52
(–CH2–CH2–CH2–), 20.81 (–NH–CH(CH3)–CH2–). C27H39N5O5
(513.30 gmol1): found m/z¼514.21([MþH]þ).
4.2.2. Acylation of 2b with Boc-glycinedsynthesis of 6b
To 2b (100 mmol) suspended in DMF (6 mL), TEA (3 equiv), were
added BocGlyOH (5 equiv), HOBt (5 equiv) and DIPCI (5 equiv). The
mixture was kept under stirring on an appropriate reaction vessel
andMW irradiated (150 W) for 20 min at a constant temperature of
90 C. The solvent was removed at 90 C under reduced pressure
and the residue was retaken in 20 mL of DCM. This solution was
washed three times with 8 mL portions of 10% aq NaHCO3 and the
organic layer dried over anhydrous MgSO4 and evaporated to dry-
ness. The residue was submitted to column chromatography on
silica using DCM/acetone as eluent. The chromatographically ho-
mogeneous product was isolated as yellow oil and identiﬁed as 6b.
4.2.2.1. 1-[(3-tert-Butyloxycarbonyl)-3-aza-1-oxopropyl]-3-{4-[(6-
methoxyquinolin-8-yl)-amino]pentyl}-1,4-diazaspiro[4.5]decan-2-
one (6b). dH (CDCl3, 300 MHz) 8.52 (dd, J¼6.08, 3.63 Hz, 1H, Q2),
7.89 (dd, J¼6.12, 3.12 Hz, 1H, Q4), 7.47 (dd, J¼6.32, 3.06 Hz, 1H, Q3),
6.34 (d, J¼2.18 Hz, 1H, Q5), 6.28 (d, J¼2.49 Hz, 1H, Q7), 5.56 (d,
J¼4.22 Hz, 1H, –NH–CH(CH3)–CH2–), 3.96 (d, J¼4.20 Hz, 2H, –CO–
CH2–NH–), 3.92–3.89 (m, 1H, –CH(CH3)–CH2–), 3.76 and 3.74 (br
sþbr s, 1H, –NH–CO–O–), 3.43–3.38 (m, 1H, –(CH2)2–CHH–), 3.28–
3.23 (m, 1H, –(CH2)2–CHH–), 2.99 (s, 2H, –CO–CH2–N(–)–), 2.97 (s,
3H, CH3–O–), 1.84–1.52 (m, 10H, –(CH2)5–), 1.48–1.46 (m, 4H, –CH2–
CH2–CH2–), 1.45 (s, 9H, –O–C(CH3)3), 1.21 and 1.17 (dþd, J¼6.54 and
6.43 Hz, 3H, –NH–CH(CH3)–). C30H43N5O5 (553.33 gmol
1): found
m/z¼554.47 ([MþH]þ).
4.2.3. Acidolytic removal of Bocdsynthesis of 5a
Compound 6a was dissolved in TFA at 30% in DCM (8 mL) and
the reaction allowed to proceed for 2 h at room temperature. Excess
TFA was neutralised by drop wise addition of 30% aq Na2CO3 until
pH 9; the supernatant oily layer formed was extracted six times
with 10 mL portions of chloroform and the organic layers pooled,
dried over anhydrous MgSO4 and evaporated to dryness.Chromatographically homogeneous yellow-orange oil was
obtained and identiﬁed as 5a.
4.2.3.1. 1-(2-Amino-1-oxoethyl)-3-{4-[(6-methoxyquinolin-8-yl)amino]-
pentyl}-2,2-dimethylimidazolidin-4-one (5a). dH (CDCl3, 300 MHz)
8.51 (dd, J¼4.16, 1.45 Hz, 1H, Q2), 7.91 (dd, J¼8.22, 1.39 Hz, 1H, Q4),
7.29 (dd, J¼8.22, 4.21 Hz,1H, Q3), 6.33 (d, J¼2.34 Hz,1H, Q5), 6.27 (d,
J¼2.29 Hz, 1H, Q7), 6.00 (d, J¼8.46 Hz, 1H, –NH–CH(CH3)–CH2–),
3.91 (s, 2H, –CO–CH2–N(CO–)–), 3.88 (s, 3H, CH3–O–), 3.69–3.60 (m,
1H, –NH–CH(CH3)–CH2–), 3.30 (s, 2H, –CO–CH2–NH2), 3.27–3.20 (m,
2H, –(CH2)2–CH2–), 1.83–1.66 (m, 6H, –CH2–CH2–CH2–, –CO–CH2–
NH2),1.61 and 1.60 (sþs, 6H, –N–C(CH3)2–N–),1.30 (d, J¼6.34 Hz, 3H,
–NH–CH(CH3)–CH2–). dC (CDCl3, 75.4 MHz) 170.54 (–CO–CH2–N–),
166.07 (–CO–CH2–NH2), 159.82 (QC6), 145.36 (QC2), 144.77 (QC8),
135.75 (QC4),135.22 (QC10),130.32 (QC9),122.32 (QC3), 97.22 (QC7),
92.20 (QC5), 81.14 (–N–C(CH3)2–N–), 55.66 (CH3–O–), 48.26 (–NH–
CH(CH3)–CH2–), 47.54 (–CO–CH2–N–), 45.54 (–CO–CH2–NH2), 40.21
(–(CH2)2–CH2–), 34.50 (–CH2–(CH2)2–), 26.20 (–CH2–CH2–CH2–),
24.95 (–N–C(CH3)(CH3)–N–), 24.90 (–N–C(CH3)(CH3)–N–), 21.13
(–NH–CH(CH3)–CH2–). C22H31N5O3 (413.24 gmol
1): found m/z¼
414.47 ([MþH]þ).
4.2.4. N1-Monoacetylation of 2adsynthesis of 7
Compound 2a (1 mmol) was suspended in DMF (20 mL), TEA
(3 equiv) and the mixture was stirred in an ice-water bath with
NaCl and acetone (10 C) for 20 min, under inert atmosphere.
Acetic anhydride (5 equiv), HOBt (5 equiv) and DIPCDI (5 equiv)
were added to the mixture, which was kept at 10 C for further
4 h. The reaction was allowed to proceed as described in Section
4.2.Work-up for product isolationwas also similar to that described
in Section 4.2, allowing to isolate chromatographically homo-
geneous yellow oil that was identiﬁed as compound 7.
4.2.4.1. 1-(1-Oxoethyl)-3-{4-[(6-methoxyquinolin-8-yl)amino]pen-
tyl}-2,2-dimethylimidazolidin-4-one (7). dH (CDCl3, 300 MHz), 8.50
(dd, J¼4.25, 1.59 Hz, 1H, Q2), 7.92 (dd, J¼8.27, 1.56 Hz, 1H, Q4), 7.29
(dd, J¼8.25, 4.24 Hz, 1H, Q3), 6.33 (d, J¼2.46 Hz, 1H, Q5), 6.28 (d,
J¼2.46 Hz, 1H, Q7), 6.06 (br s, 1H, –NH–CH(CH3)–), 3.99 (s, 2H,
–CO–CH2–N(CO–)–), 3.87 (s, 3H, CH3–O–), 3.68–3.58 (m, 1H,
–CH(CH3)–CH2–), 3.29–3.12 (m, 1H, –((CH2)2–CH2)–), 2.01 (s, 3H,
CH3–CO–N(CH2–)–), 1.82–1.64 (m, 4H, –CH2–CH2–CH2–), 1.58(1)
and 1.57(6) (sþs, 6H, –N–C(CH3)(CH3)–), 1.29 (d, J¼6.36 Hz, 3H,
–CH(CH3)–CH2–). dC (CDCl3, 75.4 MHz) 168.66 (–N–CO–CH3),
166.39 (–CO–CH2–), 159.87 (QC6), 145.21 (QC2), 144.62 (QC8),
135.55 (QC4), 135.46 (QC10), 130.43 (QC9), 122.29 (QC3), 97.48
(QC7), 92.30 (QC5), 81.06 (–N–C(CH3)2–), 56.67 (CH3–O–), 49.81
(–CO–CH2–), 48.30 (–CH(CH3)–CH2–), 40.26 (–(CH2)2–CH2), 34.46
(–CH2–(CH2)2–), 26.15 (CH3–CO–N(CH–)–), 24.83 and 24.78
(–C(CH3)(CH3)–), 24.42 (–CH2–CH2–CH2–), 21.06 (–CH(CH3)–CH2–).
C22H30N4O3 (398.23 gmol
1): found m/z¼422.07 ([MþNa]þ).
4.2.5. N,N0-Diacetylation of 2adsynthesis of 8
Compound 2a (1 mmol) was reﬂuxed in acetic anhydride
(20 equiv) for 1 h, after which the reaction mixture was evaporated
to dryness. The residue was submitted to column chromatography
on silica using DCM/MeOH as eluent. The product was isolated as
yellow oil and identiﬁed as compound 8.
4.2.5.1. 1-(1-Oxoethyl)-3-{4-[(6-methoxyquinolin-8-yl)oxoethylamino]-
pentyl}-2,2-dimethylimidazolidin-4-one (8). dH (CDCl3, 300 MHz)
8.75 (dd, J¼4.16, 1.44 Hz, 1H, Q2), 8.05 (dd, J¼8.29, 1.41 Hz, 1H, Q4),
7.36 and 7.33 (ddþdd, J¼8.17, 4.10 and 8.25, 4.19 Hz, 1H, Q3), 7.17
and 7.15 (dþd, J¼2.69 and 2.68 Hz, 1H, Q5), 7.09 (d, J¼2.68 Hz, 1H,
Q7), 5.01–4.86 (m, 1H, –CH(CH3)–CH2–), 4.01 (s, 1H, –CO–CHH–
N(CO–)–), 3.94 (s, 1H, –CO–CHH–N(CO–)–), 3.91 and 3.90 (s, 3H,
CH3–O–), 3.29–3.24 (m, 1H, –(CH2)2–CHH–), 3.02–2.97 (m, 1H,
N. Vale et al. / Tetrahedron 64 (2008) 11144–11149 11149–(CH2)2–CHH–), 2.00 and 1.97 (sþs, 3H, CH3–CO–N(CH2–)–), 1.98 (s,
3H, CH3–CO–N(CH–)–), 1.61 and 1.60 (sþs, 3H, –N–C(CH3)(CH3)–),
1.56 and 1.53 (sþs, 3H, –N–C(CH3)(CH3)–), 1.20 and 0.73 (dþd,
J¼6.76 and 6.88 Hz, 3H, –CH(CH3)–CH2–). dC (CDCl3, 75.4 MHz)
172.26 and 172.00 (CH3–CO–N(CH–)–), 168.78 and 168.75 (–N–CO–
CH3), 166.59 and 166.37 (–CO–CH2–), 157.44 and 157.34 (QC6),
148.78 and 148.75 (QC2), 142.15 and 142.12 (QC8), 138.88 and
138.60 (QC10), 135.70 and 135.66 (QC4), 130.51 (QC9), 123.89
and 123.43 (QC7), 122.57 (QC3), 106.42 and 106.39 (QC5), 81.16 and
81.05 (–N–C(CH3)2–), 56.16 and 56.13 (CH3–O–), 51.95 and 51.28
(–CH(CH3)–CH2–), 49.82 and 49.74 (–CO–CH2–), 40.32 and 40.24
(–(CH2)2–CH2), 33.89 (–CH2–(CH2)2–), 24.87 and 24.74
(–C(CH3)(CH3)–), 24.33 and 24.31 (–C(CH3)(CH3)–), 23.40 and 23.34
(–CH2–CH2–CH2–), 21.44 (CH3–CO–N(CH–)–), 20.16 (–N–CO–CH3),
17.89 (–CH(CH3)–CH2–).C24H32N4O4 (440.24 gmol
1): found m/z¼
463.87 ([MþNa]þ).
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